Evaluation of the performance of promising host transcriptional biosignatures in predicting TB progression during a 1-year prospective cohort study in Indian household contacts.

Le résumé fourni par la source

DOI of corresponing publication in Frontiers in Tuberculosis: 10.3389/ftubr.2026.1750007 The data consits of rawdata on gene expression by clinical groups; TB progressors and non-progressors. Gene expression is measured on the Fluidigm platform, expressed as ct-values, at the time of TB contact investigation in Indian households during a prospective 1-year follow-up for progression to TB. Of clincial data, gender and age groups are available. Of methodological data, quality controls and meltingpoint thresholds are given. Variable coding in the dataset:SubjectIDanonymous: Anomynized, randomly assigned number 1-192. Original PID deleted.Gender: 0=male; 1=femaleAge_strata: 1= <5years; 2= 5-14 years; 3= >14yearsFluidigm ct value: The upper cycle-limit for the Fluidigm assay: 30 cycles. Thus samples with >=cycles are given the value 999Call: PASS= The reaction meets the software’s quality‑control criteria. The amplification curve, baseline, noise level, and signal fall within acceptable limits. The Cq/Ct value is considered reliable. FLAG= No amplification (NOAMP), High noise (NOISE flag), Failed baseline/threshold detection (CTFAIL, THOLDFAIL (threshold fail)) Off‑scale signal, Abnormal melt curve (MTP) or Low signal or passive reference issues (LOWROX, BADROX)

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.